Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Swoboda

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Leukemia Research|January 23, 2026
Clinical utility of interim bone marrow biopsies in FLT3 mutant acute myeloid leukemiaVincent Lok, Katie Moffitt, Dahniel Sastow, et al.
Leukemia|May 1, 2021
Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsortedAbhishek A Mangaonkar, David M Swoboda, Terra L Lasho, et al.
Leukemia Research|June 25, 2023
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)Abhishek A Mangaonkar, David M Swoboda, Terra L Lasho, et al.
Leukemia|November 2, 2020
PTPN11 mutations are associated with poor outcomes across myeloid malignanciesDavid M Swoboda, Najla Al Ali, Onyee Chan, et al.
Leukemia Research|June 18, 2021
Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapyAnthony M Hunter, Najla Al Ali, Anne Mai, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2021
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid MalignanciesQuinto J Gesiotto, David M Swoboda, Rory M Shallis, et al.
American Journal of Hematology|February 18, 2022
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?Somedeb Ball, Akriti G Jain, Luis E Aguirre, et al.
Hematological Oncology|May 16, 2026
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid LeukemiaGeorgio Medawar, Jean-Sebastien Anoma, Elizabeth Hill, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2021
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid MalignanciesRory M Shallis, Jan Philipp Bewersdorf, David M Swoboda, et al.
Molecular Cell|April 3, 2026
U2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAsGloria R Garcia, Murali Palangat, Josquin Moraly, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Leukemia Research|January 23, 2026
Clinical utility of interim bone marrow biopsies in FLT3 mutant acute myeloid leukemiaVincent Lok, Katie Moffitt, Dahniel Sastow, et al.
Leukemia|May 1, 2021
Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsortedAbhishek A Mangaonkar, David M Swoboda, Terra L Lasho, et al.
Leukemia Research|June 25, 2023
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)Abhishek A Mangaonkar, David M Swoboda, Terra L Lasho, et al.
Leukemia|November 2, 2020
PTPN11 mutations are associated with poor outcomes across myeloid malignanciesDavid M Swoboda, Najla Al Ali, Onyee Chan, et al.
Leukemia Research|June 18, 2021
Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapyAnthony M Hunter, Najla Al Ali, Anne Mai, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2021
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid MalignanciesQuinto J Gesiotto, David M Swoboda, Rory M Shallis, et al.
American Journal of Hematology|February 18, 2022
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?Somedeb Ball, Akriti G Jain, Luis E Aguirre, et al.
Hematological Oncology|May 16, 2026
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid LeukemiaGeorgio Medawar, Jean-Sebastien Anoma, Elizabeth Hill, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2021
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid MalignanciesRory M Shallis, Jan Philipp Bewersdorf, David M Swoboda, et al.
Molecular Cell|April 3, 2026
U2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAsGloria R Garcia, Murali Palangat, Josquin Moraly, et al.
Pageof 3